Alzheimer’s Biomarkers Are Equally Accurate
Over the past decade numerous biomarkers which could potentially help predict which patients could develop Alzheimer’s disease later in life have been identified. However, these biomarkers are still being tested for reliability and practical implementation.
According to a new study from Washington University School of Medicine in St. Louis shows that these biomarkers all equally accurate for predicting the disorder years before symptoms begin to develop. The study was published in Neurology and reported by TruthDive.
The scientists studied 201 research participants from the Charles F. and Joanne Knight Alzheimer’s Disease Research Center, where they evaluated markers such as the buildup of amyloid plaques within the brain. These plaques have only recently become visible to doctors and researchers thanks to an imaging breakthrough in the past decade. The scientists also assessed the levels of various proteins in the cerebrospinal fluid such as tau proteins and amyloid fragments that are the base ingredient of brain plaques.
The participants in the study were aged 45 to 88 over an average course of four years. The longest examination was recorded over 7.5 years.
The researchers saw that all the biomarkers evaluated were equally able to identify subjects most likely to develop cognitive problems. They could also reliably be used to predict how soon impairment would begin. Next, they hope to evaluate whether demographic data such as sex, age, race, and education could be used to improve predictions.